FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

S AND EXCHANGE COMMISSION	OMB APPROVAL				
gton, D.C. 20549	OMB Number:	3235-			
	11				

Check this box if no longer subject
to Section 16. Form 4 or Form 5
obligations may continue. See
Instruction 1(h)

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

235-0287 Estimated average burden hours per response 0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940 2. Issuer Name and Ticker or Trading Symbol 5. Relationship of Reporting Person(s) to Issuer 1. Name and Address of Reporting Person ACELRX PHARMACEUTICALS INC [(Check all applicable) **EDWARDS MARK G** Director 10% Owner ACRX] Officer (give title Other (specify (Last) (First) (Middle) 3. Date of Earliest Transaction (Month/Day/Year) below) below) 06/21/2016 C/O ACELRX PHARMACEUTICALS, INC. 4. If Amendment, Date of Original Filed (Month/Day/Year) 6. Individual or Joint/Group Filing (Check Applicable 351 GALVESTON DRIVE Form filed by One Reporting Person (Street) Form filed by More than One Reporting **REDWOOD** 94063 CA Person **CITY** (City) (State) (Zip) Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned 2A. Deemed 4. Securities Acquired (A) or 6. Ownership 7. Nature 1. Title of Security (Instr. 3) 2. Transaction 5. Amount of Execution Date, Transaction Disposed Of (D) (Instr. 3, 4 Form: Direct of Indirect (Month/Day/Year) if any Code (Instr. and 5) Beneficially (D) or Beneficial (Month/Day/Year) 8) Indirect (I) Owned Ownership Following (Instr. 4) (Instr. 4)

								Code	v	Amount	(A) or (D)	Price	Reported Transact (Instr. 3	ion(s)	(,
	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Yea	4. Transac Code (li 8)		5. Num of Derivat Securit Acquir (A) or Dispos of (D) (Instr. and 5)	tive ties red sed 3, 4	6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficia Ownersh	
				Code	v	(A)	(D)	Date Exercisable		Expiration Date	Title	Amount or Number of Shares					
Common Stock (Right to Buy) ⁽¹⁾	\$2.87	06/21/2016		A		15,000		07/21/2016 ⁽²⁾)(3)	06/20/2026	Common Stock	15,000	\$0	15,000	0	D	

Explanation of Responses:

- 1. Issued pursuant to the 2011 Equity Incentive Plan.
- 2. The shares subject to the option vest as follows: 1/24th of the shares subject to the option vest in equal monthly installments over 24 months, subject to Optionee's Continuous Service on the Company's Board of Directors.
- 3. 100% Acceleration upon Change of Control.

/s/ Martha Adler, Attorney-in-06/22/2016 fact

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.